Sionna Therapeutics (NASDAQ:SION) Director Sells $21,830,973.63 in Stock

Posted by Francis Steltz on Sep 24th, 2026

Sionna Therapeutics, Inc. (NASDAQ:SION – Get Free Report) Director Ra Capital Management, L.P. sold 3,448,811 shares of the stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $6.33, for a total value of $21,830,973.63. Following the transaction, the director directly owned 3,448,812 shares in the company, valued at approximately $21,830,979.96. The trade was a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Sionna Therapeutics Price Performance

NASDAQ SION opened at $5.51 on Thursday. The company has a market cap of $249.12 million, a P/E ratio of -2.53 and a beta of 0.89. The stock has a 50-day moving average of $20.24 and a two-hundred day moving average of $32.93. Sionna Therapeutics, Inc. has a 1-year low of $4.01 and a 1-year high of $54.97.

Sionna Therapeutics (NASDAQ:SION – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.02). On average, analysts anticipate that Sionna Therapeutics, Inc. will post -2.54 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on SION shares. Citizens Jmp lowered shares of Sionna Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, August 10th. Stifel Nicolaus restated a “hold” rating and issued a $7.00 price target on shares of Sionna Therapeutics in a research note on Monday, August 10th. Royal Bank Of Canada upgraded Sionna Therapeutics from an “underperform” rating to a “sector perform” rating and set a $5.00 price objective on the stock in a research note on Monday, August 10th. Wedbush lifted their target price on Sionna Therapeutics from $5.00 to $6.00 and gave the company a “neutral” rating in a report on Tuesday, September 15th. Finally, Wall Street Zen cut Sionna Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. One investment analyst has rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $42.33.

Get Our Latest Stock Report on Sionna Therapeutics

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. State of Wyoming purchased a new stake in shares of Sionna Therapeutics during the 2nd quarter worth $35,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Sionna Therapeutics in the second quarter valued at $44,000. Quantbot Technologies LP acquired a new stake in Sionna Therapeutics in the second quarter valued at $80,000. Strs Ohio acquired a new stake in Sionna Therapeutics in the first quarter valued at $116,000. Finally, AlphaCentric Advisors LLC lifted its holdings in Sionna Therapeutics by 77.1% during the 1st quarter. AlphaCentric Advisors LLC now owns 4,818 shares of the company’s stock worth $193,000 after buying an additional 2,098 shares during the last quarter.

Sionna Therapeutics Company Profile

(Get Free Report)

Sionna Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis (CF), a genetic disease that affects the lungs and other organs. The company is developing small-molecule therapies designed to address defects in the cystic fibrosis transmembrane conductance regulator (CFTR) protein, which is responsible for transporting salt and fluids across cell membranes.

Sionna’s research is centered on nucleotide-binding domain 1 (NBD1) correctors.